Very very disappointing…. However, the fight to get out of this stock in the green goes on …..If there is anything not negative to be seen out of the CRL is that the “FDA had no questions around Mithra’s facility, the drug product manufacturing process, drug substance or bioequivalence.” Hence another long wait is likely but all is not lost ( yet).
Ann: MAYNE PHARMA provides FDA update on generic NUVARING, page-11
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$5.07 |
Change
0.050(1.00%) |
Mkt cap ! $411.9M | |||
| Open | High | Low | Value | Volume |
| $5.00 | $5.14 | $4.94 | $712.4K | 141.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1059 | $5.07 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $5.13 | 1000 | 1 |
View Market Depth
| Last trade - 16.10pm 26/06/2025 (20 minute delay) ? |
| MYX (ASX) Chart |